

The Medical Letter[®]

on Drugs and Therapeutics

Volume 58

September 12, 2016

ISSUE No.

1503

IN THIS ISSUE

In Brief: Defibrotide (*Defitelio*) for Hepatic Veno-Occlusive Disease p 120

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter[®]

on Drugs and Therapeutics

Volume 58 (Issue 1503)

September 12, 2016

[Take CME Exams](#)

IN BRIEF

Defibrotide (*Defitelio*) for Hepatic Venous-Occlusive Disease

The FDA has approved defibrotide sodium (*Defitelio* – Jazz), a mixture of mostly single-stranded polydeoxyribonucleotide sodium salts, for treatment of adults and children with hepatic venous-occlusive disease (also known as sinusoidal obstruction syndrome) and renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT). It is the first drug to be approved by the FDA for treatment of severe hepatic venous-occlusive disease. Defibrotide was approved earlier by the European Medicines Agency for the same indication.

Hepatic venous-occlusive disease is an uncommon (<2%) complication of HSCT, but it has been associated with a 70-80% mortality rate. Defibrotide has antithrombotic, anti-inflammatory, and antioxidant properties that protect hepatic endothelial cells from the damage associated with HSCT.¹

Approval of defibrotide was based on the results of three open-label studies in patients with hepatic venous-occlusive disease and multi-organ dysfunction following HSCT. In one trial in 102 adults and children, treatment with defibrotide 6.25 mg/kg every 6 hours for a median of 21.5 days was associated with a 38.2% survival rate (defined as survival at day +100 post-HSCT), compared to a 25.0% survival rate in 32 matched historical controls.² In another trial, the survival rate was 44% among 75 patients treated with defibrotide 25 mg/kg/day.³ In an unpublished study (summarized in the package insert), the survival rate was 45% among 351 patients treated with defibrotide as part of an expanded access program.

Compared with historical controls, the overall incidence of adverse effects was similar with defibrotide. The most common serious adverse effects have been hypotension and hemorrhage, particularly pulmonary alveolar hemorrhage (7%). Concurrent use of defibrotide and a systemic anticoagulant or fibrinolytic drug is contraindicated. The recommended dosage of defibrotide is 6.25 mg/kg given as a 2-hour IV infusion every 6 hours for a minimum of 21 days. The cost of 21 days of treatment with defibrotide for a patient weighing 70 kg is \$155,925.⁴

1. M Palomo et al. What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance. *Blood* 2016; 127:1719.

2. PG Richardson et al. Phase 3 trial of defibrotide for the treatment of severe venous-occlusive disease and multi-organ failure. *Blood* 2016; 127:1656.

3. PG Richardson et al. Defibrotide for the treatment of severe hepatic venous-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. *Biol Blood Marrow Transplant* 2010; 16:1005.

4. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource[®] Monthly. August 5, 2016. Reprinted with permission by First Databank, Inc. All rights reserved. ©2016. www.fdbhealth.com/policies/drug-pricing-policy.

[Follow us on Twitter](#)  [Like us on Facebook](#) 

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School; **EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D.; **CONSULTING EDITORS:** Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; Jane P. Gagliardi, M.D., M.H.S., F.A.C.P., Duke University School of Medicine; David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Franco M. Muggia, M.D., New York University Medical Center; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; F. Estelle R. Simons, M.D., University of Manitoba; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR: Susie Wong; **ASSISTANT MANAGING EDITOR:** Liz Donohue; **EDITORIAL ASSISTANT:** Cheryl Brown

EXECUTIVE DIRECTOR OF SALES: Gene Carbona; **FULFILLMENT AND SYSTEMS MANAGER:** Cristine Romatowski; **EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS:** Joanne F. Valentino; **VICE PRESIDENT AND PUBLISHER:** Yosef Wissner-Levy

Founded in 1959 by
Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. is supported solely by subscription fees and accepts no advertising, grants, or donations. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:
The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:
Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:
To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):
1 year - \$129; 2 years - \$232;
3 years - \$345. \$65 per year
for students, interns, residents, and
fellows in the US and Canada.
Reprints - \$12 each.

Site License Inquiries:
E-mail: info@medicalletter.org
Call: 800-211-2769 ext. 315
Special rates available for bulk
subscriptions.

Get Connected:  

Copyright 2016. ISSN 1523-2859

The
Medical
Letter